Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.83 |
| ▸ | SLC5A1 | P13866 | 5/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14304733 | 1.00 | SLC5A2 (0.83) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL12782042 | 1.00 | SLC5A2 (0.83) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL147932 | 0.91 | SLC5A2 (1.00) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL19312345 | 0.91 | SLC5A2 (1.00) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL9975492 | 0.91 | SLC5A2 (1.00) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL9973937 | 0.91 | SLC5A2 (1.00) | SLC5A2SLC5A1CHRM1ADRA1ASLC6A3 | |
| SCHEMBL12782038 | 0.82 | SLC5A2 (0.61) | SLC5A2SLC5A1 | |
| SCHEMBL14310972 | 0.81 | SLC5A2 (0.68) | SLC5A2SLC5A1SLC6A3 | |
| SCHEMBL14302420 | 0.81 | SLC5A2 (0.68) | SLC5A2SLC5A1SLC6A3 | |
| SCHEMBL3936832 | 0.81 | SLC5A2 (0.68) | SLC5A2SLC5A1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046346-A1 | NOVEL SGLT INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-04-15 | — | — | EP | claimed |
| US-20080027014-A1 | Novel SGLT inhibitors | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | claimed |
| WO-2008013321-A1 | NOVEL SGLT INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-31 | — | — | WO | claimed |
| EP-2046346-A1 | NOVEL SGLT INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20080027014-A1 | Novel SGLT inhibitors | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| WO-2008013321-A1 | NOVEL SGLT INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027014-A1 | Novel SGLT inhibitors | SLC5A1, SLC5A2, SLC10A1 | SLC5A2 2/4885SLC5A1 1/4885CHRM1 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.